ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Galderma Group and 3SBio side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Galderma Group3SBio
studies on the registry297107
open to participants now1246
phase 3 studies under way311
reach primary completion within a year816
programswith a study of their own in two years327

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGalderma Group3SBio
Phase 100%

3SBio: 11 of its 27 programs at phase 1

  1. 3SC009phase 1
  2. existing formulations of 611phase 1
  3. HBT-708phase 1
  4. new formulations of 611phase 1
  5. SSGJ-709phase 1

and 6 more — sign in to see them all

41%
Phase 200%

3SBio: 11 of its 27 programs at phase 2

  1. Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705phase 2
  2. SSGJ-706phase 2
  3. SPGL008phase 2
  4. SSS17phase 2
  5. SSGJ-613phase 2

and 6 more — sign in to see them all

41%
Phase 3

Galderma Group: 1 of its 3 programs at phase 3

  1. nemolizumabphase 3
33%

3SBio: 5 of its 27 programs at phase 3

  1. camtarkibartphase 3
  2. 608phase 3
  3. tivunatamigphase 3
  4. Clascoteronephase 3
  5. Minoxidilphase 3
19%
Approved, new studies

Galderma Group: 2 of its 3 programs at approved, new studies

  1. trifaroteneapproved, new study
  2. cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotionapproved, new study
67%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Galderma Group2 readouts · 1 phase 3·

Galderma Group, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. nemolizumabphase 3 · Dec 0 · NCT07074977
  2. trifaroteneapproved, new study · Dec 31 · NCT07186413
··········
3SBio11 readouts · 2 phase 3·

3SBio, Dec ’26: 5 programs whose next study reaches primary completion

  1. Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705phase 2 · Dec 0 · NCT06390774
  2. SSGJ-706phase 2 · Dec 0 · NCT07233850
  3. SSS55phase 1 · Dec 0 · NCT07058779
  4. SSS68phase 1 · Dec 0 · NCT07606976
  5. xeloxphase 2 · Dec 0 · NCT07233850

3SBio, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. 608phase 3 · Jan 14 · NCT07261644
·

3SBio, Mar ’27: 1 program whose next study reaches primary completion

  1. SSS59phase 1 · Mar 1 · NCT06944444
····

3SBio, Aug ’27: 2 programs whose next study reaches primary completion

  1. SSGJ-613phase 2 · Aug 11 · NCT07708181
  2. SSGJ-716phase 1 · Aug 29 · NCT07693738

3SBio, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. camtarkibartphase 3 · Sep 0 · NCT07767253
  2. SSGJ-709phase 1 · Sep 30 · NCT07016490
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Galderma Group

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

3SBio

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionGalderma Group3SBio
Dermatitis, Atopicboth · compare here

Galderma Group in Dermatitis, Atopic: 1 program

  1. nemolizumabphase 3

Their studies: Galderma Group’s studies of Dermatitis, Atopic in search

3SBio in Dermatitis, Atopic: 3 programs

  1. camtarkibartphase 3
  2. existing formulations of 611phase 1
  3. new formulations of 611phase 1

Their studies: 3SBio’s studies of Dermatitis, Atopic in search

Acne Vulgarisboth · compare here

Galderma Group in Acne Vulgaris: 1 program

  1. trifaroteneapproved, new study

Their studies: Galderma Group’s studies of Acne Vulgaris in search

3SBio in Acne Vulgaris: 1 program

  1. Clascoteronephase 3

Their studies: 3SBio’s studies of Acne Vulgaris in search

Psoriasisboth · compare here

3SBio in Psoriasis: 1 program

  1. 608phase 3

Their studies: 3SBio’s studies of Psoriasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Galderma Group 2 of 3 · 3SBio 6 of 27 programs (7 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.